10-Q: SI-BONE Reports 18% Revenue Growth in Second Quarter 2024, Driven by U.S. Sales

SI-BONE, Inc. announced an 18% increase in revenue for the second quarter of 2024 compared to the same period last year, primarily driven by growth in U.S. sales.

Summary

• SI-BONE, Inc. reported a revenue of $39.97 million for the three months ended June 30, 2024, a 20% increase compared to $33.31 million for the same period in 2023.
• The company's gross profit for the quarter was $31.58 million, with a gross margin of 79%, slightly lower than the 81% reported in the same quarter of the previous year.
• Operating expenses totaled $41.65 million, which included $28.97 million in sales and marketing, $4.35 million in research and development, and $8.33 million in general and administrative costs.
• The net loss for the quarter was $8.94 million, or $0.22 per share, compared to a net loss of $11.21 million, or $0.30 per share, in the second quarter of 2023.
• For the six months ended June 30, 2024, revenue reached $77.84 million, an 18% increase from $66.01 million in the same period of 2023.
• The company's net loss for the first six months of 2024 was $19.84 million, or $0.48 per share, compared to a net loss of $22.33 million, or $0.61 per share, for the same period in 2023.
• As of June 30, 2024, SI-BONE had cash and marketable securities totaling $151.5 million.
• The company has a term loan with First-Citizens Bank & Trust Company with an outstanding balance of $36.1 million as of June 30, 2024.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improved net loss per share, indicating positive momentum. However, the company is still operating at a loss and may need to raise additional capital, which introduces some uncertainty. Overall, the sentiment is positive but with some caution.

Positives

• Revenue growth of 20% in Q2 2024 and 18% for the first half of 2024 indicates strong market demand for SI-BONE's products.
• The company's net loss per share improved in both Q2 2024 and the first half of 2024 compared to the same periods in 2023.
• The company has expanded its sales force and physician training programs, which should support future growth.
• SI-BONE has a strong cash position with $151.5 million in cash and marketable securities.
• The company continues to invest in research and development, which is crucial for future product innovation and growth.

Negatives

• The gross margin decreased slightly to 79% in Q2 2024 and the first half of 2024, compared to 81% in the same periods of 2023.
• The company continues to operate at a net loss, with a loss of $8.94 million in Q2 2024 and $19.84 million for the first half of 2024.
• Operating expenses remain high, exceeding revenue in both Q2 2024 and the first half of 2024.
• The company has a significant accumulated deficit of $420.3 million as of June 30, 2024.

Risks

• The company's future performance is subject to risks and uncertainties, including those related to sales of products, changes in business strategy, regulatory and reimbursement developments, and research and development spending.
• SI-BONE may need to raise additional capital in the future, which could dilute existing shareholders.
• The company's ability to access future credit advances under its revolving line of credit is contingent on redirecting customer payments and transferring cash management account balances back to First-Citizens Bank & Trust Company.
• The company is exposed to market risks, including changes in foreign currency exchange rates and interest rates.
• The company relies on third-party manufacturers for production of its implants and instrument trays, which could be impacted by supply chain disruptions.

Future Outlook

The company believes that its existing cash and marketable securities will enable it to fund its operating expenses and capital expenditure requirements over the next 12 months. However, the company may need to raise additional capital in the future due to various factors.

Management Comments

• Management is focused on expanding access to solutions, increasing physician penetration, launching new products, addressing human capital needs, and gaining operational efficiencies.
• The company is working closely with suppliers to reduce lead time for implants and reduce cash investment in inventory.
• Management is integrating demand planning and manufacturing systems to leverage actual usage trends as they build surgical capacity.

Industry Context

The company operates in the medical device industry, specifically focusing on musculoskeletal disorders of the sacropelvic anatomy. The company's growth is influenced by factors such as physician adoption of minimally invasive procedures, reimbursement policies, and competition from other medical device companies.

Comparison to Industry Standards

• SI-BONE's revenue growth of 18% for the first half of 2024 is strong compared to the overall medical device industry, which typically sees single-digit growth.
• Companies like Globus Medical and NuVasive, which also focus on spinal and orthopedic solutions, have reported similar growth rates in certain segments, but SI-BONE's focus on the sacropelvic area provides a unique market position.
• The company's gross margin of 79% is within the typical range for medical device companies, but there is room for improvement to reach the higher end of the industry standard.
• SI-BONE's continued net losses are not uncommon for growth-stage medical device companies, but the company will need to demonstrate a path to profitability to ensure long-term sustainability.
• Compared to companies like Medtronic and Stryker, which have a broader product portfolio, SI-BONE's focus on a specific niche allows for deeper market penetration but also carries the risk of being overly reliant on a single product category.

Related Party Transactions

• The company had a joint development agreement with SeaSpine Orthopedics Corporation, which merged with Orthofix Medical, Inc. However, SeaSpine is no longer a related party of the company.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and any potential future capital raises.
• Employees will be impacted by the company's ability to recruit, develop, and retain talent.
• Customers (physicians and healthcare facilities) will be impacted by the company's ability to provide innovative and effective solutions.
• Suppliers will be impacted by the company's purchase commitments and obligations.

Next Steps

• The company will continue to focus on expanding access to solutions, increasing physician penetration, launching new products, addressing human capital needs, and gaining operational efficiencies.
• The company anticipates the results for the primary endpoint of the SILVIA study in 2025.
• The company anticipates publishing follow-up results of the SAFFRON study in 2025.

Key Dates

Keywords

sacroiliac joint dysfunction, spinal fusion, pelvic fixation, medical devices, orthopedic implants, iFuse, revenue growth, surgical procedures, clinical trials, reimbursement